New! Sign up for our free email newsletter.
Science News
from research organizations

Another potential mechanism links androgen deprivation therapy to cardiovascular mortality

Study finds that androgen deprivation therapy for prostate cancer causes prolongation of QTc interval duration which could explain part of the increased risk of cardiovascular mortality and sudden cardiac death in these patients

Date:
May 21, 2018
Source:
Brigham and Women's Hospital
Summary:
The mechanisms by which ADT may lead to an increased risk of sudden death were unclear.
Share:
FULL STORY

Prostate cancer is the most common cancer in men in the US. As the prostate is a testosterone-responsive gland, androgen deprivation therapy (ADT) is the cornerstone of treatment in these men, with approximately 50 percent of prostate cancer patients starting ADT within a year of diagnosis. This therapy works by suppressing testosterone production, which in turn slows the growth of the cancer. Although ADT results in improved survival in a subset of these patients, it has many side effects, including increased risk of cardiovascular disease and sudden death. The mechanisms by which ADT may lead to an increased risk of sudden death were unclear. Now, a team of researchers from BWH has shed some light on this issue and their findings are published findings in the Journal of the Endocrine Society.

"We showed that ADT results in electrophysiological changes in the heart," said first author Thiago Gagliano-Jucá, MD, PhD, a research fellow in the Section on Men's Health at BWH. "The time it takes for these cells to be able to contract again after each beat increased following ADT, and prolongation of this time is a known risk factor of ventricular arrhythmias. We are trying to piece together how ADT might be resulting in sudden deaths in some men."

Testosterone is known to shorten the time necessary for the cardiac cells (cardiomyocytes) to be able to contract again after a previous contraction. Reduced testosterone levels as a result of ADT prolongs this time, which is known as the QTc interval on the electrocardiogram. This prospective study of over 70 men found that men receiving ADT experience a prolongation of their QTc interval duration compared with those men with prostate cancer who were not receiving ADT. QTc prolongation is well established to be associated with a higher risk of arrhythmia, suggesting that the prolongation of the QTc interval during ADT might be the mechanism behind some of these cardiac events.

"Oncologists should monitor QTc interval in patients receiving ADT, especially those patients who are taking medications that also prolong QTc interval" said Gagliano-Jucá.


Story Source:

Materials provided by Brigham and Women's Hospital. Note: Content may be edited for style and length.


Journal Reference:

  1. Thiago Gagliano-Jucá, Thomas G Travison, Philip W Kantoff, Paul L Nguyen, Mary-Ellen Taplin, Adam S Kibel, Grace Huang, Richelle Bearup, Haley Schram, Robert Manley, Yusnie M Beleva, Robert R Edwards, Shehzad Basaria. Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. Journal of the Endocrine Society, 2018; 2 (5): 485 DOI: 10.1210/js.2018-00039

Cite This Page:

Brigham and Women's Hospital. "Another potential mechanism links androgen deprivation therapy to cardiovascular mortality." ScienceDaily. ScienceDaily, 21 May 2018. <www.sciencedaily.com/releases/2018/05/180521143829.htm>.
Brigham and Women's Hospital. (2018, May 21). Another potential mechanism links androgen deprivation therapy to cardiovascular mortality. ScienceDaily. Retrieved October 7, 2024 from www.sciencedaily.com/releases/2018/05/180521143829.htm
Brigham and Women's Hospital. "Another potential mechanism links androgen deprivation therapy to cardiovascular mortality." ScienceDaily. www.sciencedaily.com/releases/2018/05/180521143829.htm (accessed October 7, 2024).

Explore More

from ScienceDaily

RELATED STORIES